Company: EDSA
Filing Date: 2025-02-13
Form Type: 8-K
Source: 0001171843-25-000796
Chunk: 4

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-13
Form: 8-K
Item: Item 3.03
Chunk 4
---
Item 3.03 Material Modiﬁcation to Rights of Security Holders.

The description of the terms of the Preferred Shares under Item 1.01 and
Item 5.03 is incorporated herein by reference.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment
of Principal Officers.

On February 12, 2025, in connection with the closing of the Purchase Agreement
and pursuant to the terms of the IRA, the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors with
an initial term expiring at the next general meeting of shareholders of the Company. Dr. Liu will also serve on the Compensation Committee
of the Board of Directors.

David Liu, age 39, has over 10 years of investment experience within the
biopharmaceutical industry. From January 2023 to March 2024, and since December 2024, he has served as a Senior Analyst at Velan Capital
Investment Management LP, a healthcare dedicated investment firm based in Alpharetta, Georgia. Prior to his current position, he served
as a Biotech Analyst at Altium Capital Management, LP, an investment firm focused on healthcare companies from January 2019 to November
2022. He received his B. S. in Biological Sciences from Stanford University and his Ph. D. in Molecular Biology from Weil Cornell Graduate
School of Medical Sciences. Dr. Liu is qualified to serve on the Board of Directors because of experience in the biopharmaceutical industry.

Dr. Liu will be eligible to receive the same compensation as the Company’s
other non-employee directors as described under “ Director Compensation” in the Company’s Form 10-K for the fiscal year
ended September 30, 2024, filed with the Securities and Exchange Commission on December 13, 2024, as amended on December 20, 2024. In
addition, the Company intends to enter into an indemnification agreement with Dr. Liu, in substantially the form filed as Exhibit 10.4
to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference.

The Board of Directors has affirmatively determined that (i) Dr. Liu is
independent under the rules of The Nasdaq Stock Market LLC, (ii) other than the IRA disclosed above, there is no arrangement or understanding
between Dr. Liu and any other person pursuant